Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Eli Lilly and Company Snapshot 7 Eli Lilly and Company Overview 7 Key Information 7 Key Facts 7 Eli Lilly and Company - Research and Development Overview 8 Key Therapeutic Areas 8 Eli Lilly and Company - Pipeline Review 17 Pipeline Products by Stage of Development 17 Pipeline Products - Monotherapy 18 Pipeline Products - Combination Treatment Modalities 19 Pipeline Products - Partnered Products 20 Pipeline Products - Out-Licensed Products 22 Eli Lilly and Company - Pipeline Products Glance 24 Eli Lilly and Company - Late Stage Pipeline Products 24 Eli Lilly and Company - Clinical Stage Pipeline Products 27 Eli Lilly and Company - Early Stage Pipeline Products 31 Eli Lilly and Company - Drug Profiles 33 baricitinib 33 duloxetine hydrochloride DR 36 ixekizumab 38 necitumumab 39 olaratumab 42 ramucirumab 44 cetuximab 50 abemaciclib 57 AMG-5041 59 insulin peglispro 60 LY-2951742 62 odelepran hydrochloride 64 solanezumab 65 tadalafil 67 galunisertib 69 blosozumab 71 edivoxetine hydrochloride 72 emibetuzumab 74 erteberel 75 icrucumab 76 insulin lispro U100 77 landogrozumab 79 LY-2510924 80 LY-2623091 82 LY-2874455 83 LY-2928057 84 LY-2944876 85 LY-3015014 87 LY-3016859 88 LY-3023414 89 LY-3074828 91 merestinib 92 prexasertib 93 ralimetinib mesylate 95 LY-2780301 96 LY-3039478 97 Biologic 6 for Diabetes 98 Biologic for Crohn's Disease 99 Biologic for Diabetic Nephropathy 100 Biologic for Hypoglycemia 101 Biologic for Lupus 102 Biologic for Neutrophilic Dermatosis 103 Biologic for Renal Anemia 104 dulaglutide 105 insulin lispro U200 108 LY-2599666 109 LY-2969822 110 LY-3002813 111 LY-3009120 112 LY-3022855 113 LY-3025876 114 LY-3041658 115 LY-3050258 116 LY-3076226 117 LY-3079514 118 LY-3090106 119 LY-3108743 120 LY-3114062 121 LY-3127760 122 LY-3127804 123 LY-3143753 124 LY-3154207 125 LY-3164530 126 LY-3185643 127 LY-3200327 128 LY-3202626 129 LY-3337641 130 LY-900014 131 Recombinant Protein for Parkinson's Disease 132 Small Molecule 4 for Diabetes 133 cercosporamide 134 CPZEN-45 136 LLY-2707 137 LSN-2463359 138 LSN-2535717 139 LSN-2814617 140 LY-2109761 141 LY-2607540 142 LY-2811376 + LY-3002813 143 LY-2857785 144 LY-344545 145 Monoclonal Antibody Conjugate 2 for Oncology 146 Monoclonal Antibody Conjugate 3 for Oncology 147 Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology 148 ND-09759 149 Small Molecule to Agonize TR-Beta for Dyslipidemia 150 Small Molecule to Antagonize mGlu5 for Pain 151 Drugs for Oncology 152 IC-87201 153 Monoclonal Antibodies for Undisclosed Indication 154 Small Molecule for Type 2 Diabetes 155 Small Molecule to Antagonize EP4 Receptor for Pain and Inflammation 156 Small Molecule to Inhibit MPGES-1 for Inflammation and Pain 157 Eli Lilly and Company - Pipeline Analysis 158 Eli Lilly and Company - Pipeline Products by Target 158 Eli Lilly and Company - Pipeline Products by Route of Administration 165 Eli Lilly and Company - Pipeline Products by Molecule Type 166 Eli Lilly and Company - Pipeline Products by Mechanism of Action 167 Eli Lilly and Company - Recent Pipeline Updates 171 Eli Lilly and Company - Dormant Projects 203 Eli Lilly and Company - Discontinued Pipeline Products 207 Discontinued Pipeline Product Profiles 209 Eli Lilly and Company - Company Statement 220 Eli Lilly and Company - Locations and Subsidiaries 224 Head Office 224 Other Locations & Subsidiaries 224 Eli Lilly and Company - Key Manufacturing Facilities 232 Appendix 233 Methodology 233 Coverage 233 Secondary Research 233 Primary Research 233 Expert Panel Validation 233 Contact Us 233 Disclaimer 234

List of Tables Eli Lilly and Company, Key Information 15 Eli Lilly and Company, Key Facts 15 Eli Lilly and Company - Pipeline by Indication, 2016 17 Eli Lilly and Company - Pipeline by Stage of Development, 2016 25 Eli Lilly and Company - Monotherapy Products in Pipeline, 2016 26 Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2016 27 Eli Lilly and Company - Partnered Products in Pipeline, 2016 28 Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2016 29 Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016 30 Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2016 31 Eli Lilly and Company - Pre-Registration, 2016 32 Eli Lilly and Company - Filing rejected/Withdrawn, 2016 33 Eli Lilly and Company - Phase III, 2016 34 Eli Lilly and Company - Phase II, 2016 35 Eli Lilly and Company - Phase I, 2016 37 Eli Lilly and Company - Preclinical, 2016 39 Eli Lilly and Company - Discovery, 2016 40 Eli Lilly and Company - Pipeline by Target, 2016 166 Eli Lilly and Company - Pipeline by Route of Administration, 2016 173 Eli Lilly and Company - Pipeline by Molecule Type, 2016 174 Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2016 175 Eli Lilly and Company - Recent Pipeline Updates, 2016 179 Eli Lilly and Company - Dormant Developmental Projects,2016 211 Eli Lilly and Company - Discontinued Pipeline Products, 2016 215 Eli Lilly and Company, Subsidiaries 232 Eli Lilly and Company, Key Manufacturing Facilities 240 List of Figures Eli Lilly and Company - Pipeline by Top 10 Indication, 2016 17 Eli Lilly and Company - Pipeline by Stage of Development, 2016 25 Eli Lilly and Company - Monotherapy Products in Pipeline, 2016 26 Eli Lilly and Company - Partnered Products in Pipeline, 2016 28 Eli Lilly and Company - Out-Licensed Products in Pipeline, 2016 30 Eli Lilly and Company - Pipeline by Top 10 Target, 2016 166 Eli Lilly and Company - Pipeline by Route of Administration, 2016 173 Eli Lilly and Company - Pipeline by Molecule Type, 2016 174 Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2016 175